Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans

Pharmacogenetics and Genomics

Volumn 21, Issue 4, 2011, Pages 171-178

  Kohli, Utkarsh ^a,e   Hahn, Maureen K ^a,f,g   English, Brett A ^b   Sofowora, Gbenga G ^a,e   Muszkat, Mordechai ^a,e   Li, Chun ^d   Blakely, Randy D ^b,c,g   Stein, C Michael ^a,e   Kurnik, Daniel ^a,e,h,i  

^a University of Medicine   (United States)

^b Departments of Pharmacology and Pathology   (United States)

^c UT Southwestern   (United States)

^d Departments of Biostatistics   (United States)

^e Divisions of Clinical Pharmacology   (United States)

^f Divisions of Genetic Medicine   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ TEL AVIV UNIVERSITY   (Israel)

Author keywords

Blood pressure; Exercise; Norepinephrine t.ransporter.; Polymorphism

Indexed keywords

NORADRENALIN; NORADRENALIN TRANSPORTER;

ADULT; ARTICLE; BLOOD PRESSURE; CATECHOLAMINE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; EXERCISE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

MUS MUSCULUS;

EID: 79955480401     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328344f63e     Document Type: Article

References (38)

1. Bouchard C, Rankinen T. Individual differences in response to regular physical activity. Med Sci Sports Exerc 2001; 33:S446-S451. (Pubitemid 32524736)
2. McCaffery JM, Pogue-Geile MF, Ferrell RE, Petro N, Manuck SB. Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens 2002; 20:1105-1114. (Pubitemid 34913628)
3. Rice T, Rankinen T, Province MA, Chagnon YC, Perusse L, Borecki IB, et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation 2000; 102:1956-1963.
4. Ingelsson E, Larson MG, Vasan RS, O'Donnell CJ, Yin X, Hirschhorn JN, et al. Heritability, linkage, and genetic associations of exercise treadmill test responses. Circulation 2007; 115:2917-2924. (Pubitemid 46912094)
5. Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, Finney C, et al. Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 2004; 110:1191-1196. (Pubitemid 39202331)
6. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al. Orthostatic intolerance and tachycardia associated with norepinephrinetransporter deficiency. N Engl J Med 2000; 342:541-549. (Pubitemid 30117894)
7. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 2003; 23:4470-4478. (Pubitemid 36706177)
8. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A 2006; 103:19164-19169. (Pubitemid 350002844)
9. Kim CH,Waldman ID, Blakely RD, Kim KS. Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Ann N Y Acad Sci 2008; 1129:256-260. (Pubitemid 351990292)
10. Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, Xie HG, et al. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta blockade. Pharmacogenet Genomics 2008; 18:895-902.
11. Ainsworth BE, Haskell WL,Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32:S498-S504.
12. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73:366-371. (Pubitemid 36403596)
13. Kurnik D, Cunningham AJ, Sofowora GG, Kohli U, Li C, Friedman EA, et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta-(1)-adrenergic blockade in humans. Pharmacogenomics 2009; 10:1581-1587.
14. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161. (Pubitemid 40066429)
15. He HB, Deegan RJ, Wood M, Wood AJ. Optimization of high-performance liquid chromatographic assay for catecholamines: determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. J Chromatogr 1992; 574:213-218.
16. Dupont WD. Statistical modeling for biomedical researchers: a simple introduction to the analysis of complex data. Cambridge: Cambridge University Press; 2002.
17. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, Dupont WD, Scheinin M, et al. Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension 2008; 51:406-411. (Pubitemid 351159957)
18. Kohli U, Muszkat M, Sofowora GG, Harris PA, Friedman EA, Dupont WD, et al. Effects of variation in the human alpha(2A)- and alpha(2C)-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain 2010; 14:154-159.
19. Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, et al. Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Genes Brain Behav 2008; 7:487-495. (Pubitemid 351590936)
20. Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Neuropsychobiology 2004; 50:301-304. (Pubitemid 39482669)
21. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575-1580. (Pubitemid 39201453)
22. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000; 3:465-471. (Pubitemid 30495628)
23. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002; 105:347-353. (Pubitemid 34106184)
24. Moldovanova I, Schroeder C, Jacob G, Hiemke C, Diedrich A, Luft FC, et al. Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. Hypertension 2008; 51:1203-1209. (Pubitemid 351398983)
25. Singh JP, Larson MG, Manolio TA, O'Donnell CJ, Lauer M, Evans JC, et al. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension: the Framingham heart study. Circulation 1999; 99:1831-1836. (Pubitemid 29181411)
26. Mundal R, Kjeldsen SE, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Exercise blood pressure predicts cardiovascular mortality in middle-aged men. Hypertension 1994; 24:56-62. (Pubitemid 24195404)
27. Filipovsky J, Ducimetiere P, Safar ME. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 1992; 20:333-339.
28. Lewis GD, Gona P, Larson MG, Plehn JF, Benjamin EJ, O'Donnell CJ, et al. Exercise blood pressure and the risk of incident cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 101:1614-1620.
29. Delp MD, O'Leary DS. Integrative control of the skeletal muscle microcirculation in the maintenance of arterial pressure during exercise. J Appl Physiol 2004; 97:1112-1118. (Pubitemid 39121440)
30. Kirchheim HR. Systemic arterial baroreceptor reflexes. Physiol Rev 1976; 56:100-177.
31. Hahn MK, Mazei-Robison MS, Blakely RD. Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol 2005; 68:457-466. (Pubitemid 41058309)
32. Runkel F, Bruss M, Nothen MM, Stober G, Propping P, Bonisch H. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter. Pharmacogenetics 2000; 10:397-405. (Pubitemid 30433573)
33. Esler M. Clinical application of noradrenaline spillover methodology: delineation of regional human sympathetic nervous responses. Pharmacol Toxicol 1993; 73:243-253. (Pubitemid 24011335)
34. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990; 70:963-985. (Pubitemid 20364820)
35. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93:1667-1676. (Pubitemid 26131343)
36. Zouhal H, Jacob C, Delamarche P, Gratas-Delamarche A. Catecholamines and the effects of exercise, training and gender. Sports Med 2008; 38:401-423. (Pubitemid 351550538)
37. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, et al. Sympathoneural and adrenomedullary functional effects of alpha2Cadrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 2005; 15:143-149. (Pubitemid 40569900)
38. Apparsundaram S, Moore KR, Malone MD, Hartzell HC, Blakely RD. Molecular cloning and characterization of an L-epinephrine transporter from sympathetic ganglia of the bullfrog, Rana catesbiana. J Neurosci 1997; 17:2691-2702. (Pubitemid 27155002)